Chronic Pain, Peripheral Neuralgia, Peripheral Neuropathy
Conditions
Keywords
PNS, Peripheral nerve stimulation, micro-IPG, peripheral nerve stimulator, chronic pain
Brief summary
This post market study is being conducted to document the comparative effectiveness and safety of peripheral nerve stimulation plus conventional medical management versus conventional medical management alone in the treatment of chronic, intractable peripheral neuralgia of post-traumatic or postsurgical origin. This is a prospective, minimal risk, multi-center, randomized control trial.
Detailed description
Multi-center, prospective, open-label, randomized controlled trial (RCT) comparing PNS plus CMM with CMM alone. Subjects will be randomized to receive: Arm 1: Nalu Neurostimulation System for PNS plus CMM Arm 2: CMM alone Consented subjects will receive a baseline evaluation and then be randomized 2:1 into one of two arms: 1) PNS+CMM arm or 2) CMM arm. Subjects assigned to Arm 1 will undergo a trial implant period using best clinical practices. Those subjects who pass the trial implant will receive the permanent implant. At the 3-month end point, subjects in Arm 2 will be given the option to crossover into Arm 1 beginning with a trial implant. All Arm 1 patients receiving a permanent implant will be followed for a total of 36 months after permanent implantation.Arm 2 patients who do not crossover will be followed for a total of 36 months from randomization.
Interventions
The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
Conventional Medical Management is the best standard of care treatment for the patient
Sponsors
Nalu Medical, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is between 18 to 80 years of age at the time of enrollment. 2. Subject would have been prescribed PNS therapy regardless of participation in this study; the use of the Nalu device must be on-label. 3. Subject has been diagnosed with one or more of the conditions listed below in the low back, shoulder, knee, or foot (including ankle): * Post-surgical/post-traumatic peripheral neuralgia including but not limited to pain due to peripheral nerve injury, post-surgical scar formation, nerve entrapment * Mononeuropathy, specified or unspecified or in diseases classified elsewhere * Other neuralgia or neuropathic pain * Osteoarthritic pain 4. Subject has chronic (defined as at least 6 months duration), intractable peripheral neuropathic pain, exclusive of the craniofacial region; any nociceptive pain must be less prominent than the neuropathic pain. Pain should have a predominant neuropathic component as per the investigator's clinical assessment. 5. Subject should have a pain score of at least 6, in the target area of pain, as recorded on the BPI-Q5 (NRS) at screening. 6. Subject is willing to cooperate with the study requirements including, compliance with the study procedures and completion of all study visits. 7. Subject reported stable pain (non-escalating) for 60 days prior to signing informed consent. 8. Subject is currently receiving CMM and has had stable pain medication use and dosage for 30 days prior to signing informed consent. 9. Subject is psychologically qualified to receive a peripheral nerve stimulator as per the clinician's standard clinical practice and judgment and does not have clinically relevant psychological condition(s) that would interfere with their ability to accurately report outcomes or complete study procedures. 10. Subject has demonstrated the ability to appropriately place the adhesive clip in the location where the IPG is most likely to be implanted. Alternatively, subject is able to appropriately use the relief belt and/or limb cuff to keep the Therapy Disc in place.
Exclusion criteria
Subject currently has an active implantable medical device such as a drug pump, spinal cord stimulator, peripheral nerve stimulator, sacral nerve stimulator, deep brain stimulator, and/or cardiac pacemaker. 2\. Subject has previously failed PNS or Spinal Cord Stimulation (SCS) or Dorsal Root Ganglion (DRG) therapy (trial or permanent implant). See note below. 3\. Pain is completely absent at rest. 4. Patient has clinical evidence of complex regional pain syndrome (CRPS), peripheral neuralgia of metabolic origin, post-herpetic neuralgia, biochemical evidence of a metabolic or genetic neuropathy (e.g., Charcot'- Marie- Tooth Disease) or mixed motor/sensory polyneuropathy. 5\. Subject has a medical condition that would prevent them from participating in the current study per investigator's or medical monitor's judgment. 6\. Subject has had a successful (≥ 50% pain relief) interventional procedure within the past 3 months to treat the same pain condition(s) being examined in this study including, nerve blocks. 7\. Uncontrolled depression or uncontrolled psychiatric disorders 8. Subject is currently participating in another clinical investigation with an active treatment arm. 9\. Subject is allergic or sensitive to materials used in the device components including, skin adhesives or does not tolerate the wearable aspect of the device. 10\. Subject has pending or ongoing legal issues (including unresolved worker's compensation claims or equivalent) or other conflicting secondary gain issues related to their chronic pain condition. 11\. Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, or progressive peripheral vascular disease that has not been medically corrected. 12\. Subject has an active systemic infection. 13. Subject is unable to read and/or write in English or give informed consent. 14. Subject has a life expectancy of less than 1 year. 15. Subject has an active malignant neoplasm (metastatic or local) or evidence of paraneoplastic syndrome. 16\. Subject with uncontrolled diabetes mellitus, showing signs of diabetic neuropathy, as evidenced by a neurological exam and a HbA1c test. 17\. Subject has evidence of an alcohol or drug dependency within the last 6 months prior to enrollment. 18\. Subject is pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile or be at least 1 year post-menopausal). 19\. Subject is nursing/breastfeeding. 20. Subject is on ≥90 mg-morphine equivalents per 24 hours. 21. Subject has undergone an ablative treatment of the target peripheral nerve, or proximal nerve trunk giving rise to the target nerve, or dorsal roots (and DRGs) that ultimately make up the target nerve. No ablative procedures directed at the spinal cord, dorsal roots, or peripheral nerve(s) being treated in the study. To note, subjects who have undergone RF ablation of the dorsal rami, cool pulsed RF of the facet innervation may be considered for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness: Responder Rates between the 2 groups | 3-months | Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the Numeric Rating Scale (0-10; 0=no pain, 10=worst pain imaginable) |
| Safety: Rate of serious and non-serious device effects | 3-months | Rate of serious and non-serious adverse device events between groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Responder Rates | 6-months,12 months, 24 months and 36-months | Difference in responder rates between groups. Responder rate is defined as the percent of subjects with 50% or greater pain relief from baseline, based on the BPI-Q5 (NRS,0-10 where, 0= no pain; 10=worst pain imaginable). |
| Functional Outcomes: Change in Oswestry Disability Index (ODI) score from baseline to protocol defined timepoints | 3 months, 6-months,12 months, 24 months and 36-months | Change in patient reported ODI from baseline with comparisons between groups. The ODI is scored from 0-100% disability. A lower score, compared to baseline, indicates improvement in ODI. |
| Functional Outcomes: Change in Beck's Depression Inventory (BDI) score from baseline | 3 months, 6-months,12 months, 24 months and 36-months | Change in patient reported depression from baseline with comparison between groups. The BDI is scored from 0-63. A lower score at follow-up, compared to baseline, indicates an improvement in depression symptoms and mood. |
| Functional Outcomes: Patient Global Impression of Change (PGIC) | 3 months, 6-months,12 months, 24 months and 36-months | PGIC is reported by the patient post-implant, on a 7-point likert scale to indicate overall changes in mood, activity, emotional well-being and quality of life. Proportion of patients showing improvement, worsening or no change, will be collected and reported at protocol specified time points. |
| Safety Assessment | 6-months,12 months, 24 months and 36-months | Rate of serious and non-serious device effects |
Countries
United States
Contacts
STUDY_DIRECTORPatrick Martin
Nalu Medical, Inc.
Outcome results
None listed